Interview with Dr David Orloff

Close Concerns recently had the distinct honor of discussing the recent FDA cardiovascular risk assessment guidelines for diabetes drugs with Dr. David Orloff, the former director of the division of metabolism and endocrinology products at FDA, and currently executive director of regulatory affairs at Medpace, Inc.

Enter your details below to view the free whitepaper

By downloading this Whitepaper, you acknowledge that Global Data Plc may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how Global Data Plc may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.